ABVC: ABVC BioPharma, Inc. Stock

by  •  • Comments Off on ABVC: ABVC BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 16.75
Enterprise Value ($M) 19.73
Book Value ($M) 8.13
Book Value / Share 0.77
Price / Book 2.06
NCAV ($M) -4.70
NCAV / Share -0.45
Price / NCAV -3.56

Profitability (mra)
Return on Invested Capital (ROIC) -0.86
Return on Assets (ROA) -0.98
Return on Equity (ROE) -6.06

Liquidity (mrq)
Quick Ratio 0.28
Current Ratio 0.28

Balance Sheet (mrq) ($M)
Current Assets 1.66
Assets 14.49
Liabilities 6.36
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.15
Operating Income -8.22
Net Income -10.52
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -4.24
Cash from Investing -0.36
Cash from Financing 3.92

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Lind Global Fund II LP 9.90

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-15 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSU
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2023-11-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-15 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 591,333 1,880,471 31.45
2024-04-25 1,678,069 5,357,784 31.32
2024-04-24 1,720,125 663,860 259.11
2024-04-23 2,882,515 799,134 360.70

(click for more detail)

Similar Companies
AADI – Aadi Bioscience, Inc. ABEO – Abeona Therapeutics Inc.
ABIO – ARCA biopharma, Inc. ACB – Aurora Cannabis Inc.
ACHV – Achieve Life Sciences, Inc.


Financial data and stock pages provided by
Fintel.io